The classifier detects elevated expression of circulating serum amyloid A1, serum amyloid A2 and C-reactive protein in patients who are likely to benefit from combination immunotherapy and chemotherapy (NSCLC “Poor”) when compared to patients without elevated SAA1, SAA2 and CRP levels who are likely to benefit from single-agent immunotherapy (NSCLC “Good”) [22,23,24]. This evidence concerns the gene SAA2 and non-small cell lung carcinoma.